blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2043685

EP2043685 - PREVENTION OF RASH IN PATIENTS UNDERGOING ANTI-EGFR THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.10.2016
Database last updated on 03.06.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Genmab A/S
Bredgade 34 E
1260 Copenhagen K / DK
[2013/12]
Former [2009/19]For all designated states
Genmab A/S
Bredgade 34 P.O. Box 9068
1260 Copenhagen K / DK
Former [2009/15]For all designated states
Genmab A/S
Toldbodgade 33
1253 Copenhagen K / DK
Inventor(s)01 / EDVARDSEN, Klaus
Klampenborgvej 26
2930 Klampenborg / DK
02 / LISBY, Steen
Nyelandsvej 83, 3.tv.
2000 Frederiksberg / DK
03 / BAADSGAARD, Ole
Tuborg Sundpark 10, 1.tv
2900 Hellerup / DK
 [2009/15]
Representative(s)Genmab A/S
Carl Jacobsens Vej 30
2500 Valby / DK
[N/P]
Former [2015/52]Genmab A/S
Bredgade 34 E
1260 Copenhagen K / DK
Former [2012/09]Genmab A/S
Bredgade 34
P.O. Box 9068
1260 Copenhagen K / DK
Former [2010/11]Jensen, Dorte Kold
Genmab A/S Bredgade 34 P.O. Box 9068
1260 Copenhagen K / DK
Former [2009/17]Abildgren, Michael Padkjaer
Genmab A/S Toldbodgade 33 P.O. Box 9068
DK-1253 Copenhagen K / DK
Application number, filing date07764464.903.07.2007
[2009/15]
WO2007DK00334
Priority number, dateDK2006000091503.07.2006         Original published format: DK 200600915
DK2007000072715.05.2007         Original published format: DK 200700727
DK2007000090122.06.2007         Original published format: DK 200700901
[2009/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008003317
Date:10.01.2008
Language:EN
[2008/02]
Type: A1 Application with search report 
No.:EP2043685
Date:08.04.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 10.01.2008 takes the place of the publication of the European patent application.
[2009/15]
Type: B1 Patent specification 
No.:EP2043685
Date:23.12.2015
Language:EN
[2015/52]
Search report(s)International search report - published on:EP10.01.2008
ClassificationIPC:A61P17/00, A61K39/395
[2015/30]
CPC:
C07K16/2863 (EP,US); A61K39/3955 (EP,US); A61K45/06 (EP,US);
A61P17/00 (EP); A61P37/06 (EP); C07K16/244 (EP,US);
A61K2039/507 (EP,US) (-)
C-Set:
A61K39/3955, A61K2300/00 (EP,US)
Former IPC [2009/15]A61K39/395
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/52]
Former [2009/15]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL03.02.2009
BA03.02.2009
HR03.02.2009
MK03.02.2009
RS03.02.2009
TitleGerman:PRÄVENTION VON HAUTAUSSCHLAG BEI PATIENTEN IN ANTI-EGFR-THERAPIE[2015/30]
English:PREVENTION OF RASH IN PATIENTS UNDERGOING ANTI-EGFR THERAPY[2009/15]
French:PRÉVENTION D'UNE ÉRUPTION CUTANÉE SUR DES PATIENTS SUBISSANT UNE THÉRAPIE ANTI-EGFR[2009/15]
Former [2009/15]PRÄVENTION VON HAUTAUSSCHLAG BEI PATIENTEN UNTER EINER ANTI-EGFR-THERAPIE
Entry into regional phase03.02.2009National basic fee paid 
03.02.2009Designation fee(s) paid 
03.02.2009Examination fee paid 
Examination procedure03.02.2009Examination requested  [2009/15]
10.02.2009Amendment by applicant (claims and/or description)
27.09.2013Despatch of a communication from the examining division (Time limit: M06)
08.05.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.07.2014Reply to a communication from the examining division
18.06.2015Cancellation of oral proceeding that was planned for 06.07.2015
02.07.2015Communication of intention to grant the patent
06.07.2015Date of oral proceedings (cancelled)
28.10.2015Fee for grant paid
28.10.2015Fee for publishing/printing paid
28.10.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.09.2013
Opposition(s)26.09.2016No opposition filed within time limit [2016/48]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
10.07.2014Request for further processing filed
10.07.2014Full payment received (date of receipt of payment)
Request granted
22.07.2014Decision despatched
Fees paidRenewal fee
31.07.2009Renewal fee patent year 03
14.07.2010Renewal fee patent year 04
12.07.2011Renewal fee patent year 05
13.07.2012Renewal fee patent year 06
10.07.2013Renewal fee patent year 07
14.07.2014Renewal fee patent year 08
10.07.2015Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.07.2007
AT23.12.2015
BE23.12.2015
BG23.12.2015
CY23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
TR23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
IE03.07.2016
LU03.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
[2018/38]
Former [2018/33]HU03.07.2007
AT23.12.2015
BE23.12.2015
CY23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
TR23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
IE03.07.2016
LU03.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
Former [2018/29]HU03.07.2007
AT23.12.2015
BE23.12.2015
CY23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
TR23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
IE03.07.2016
LU03.07.2016
CH31.07.2016
LI31.07.2016
Former [2018/28]HU03.07.2007
AT23.12.2015
BE23.12.2015
CY23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
IE03.07.2016
LU03.07.2016
CH31.07.2016
LI31.07.2016
Former [2017/41]AT23.12.2015
BE23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
IE03.07.2016
LU03.07.2016
CH31.07.2016
LI31.07.2016
Former [2017/22]AT23.12.2015
BE23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
MC23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
CH31.07.2016
LI31.07.2016
Former [2017/13]AT23.12.2015
BE23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SI23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
Former [2017/03]AT23.12.2015
BE23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
Former [2016/46]AT23.12.2015
CZ23.12.2015
DK23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
Former [2016/38]AT23.12.2015
CZ23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SK23.12.2015
GR24.03.2016
IS23.04.2016
PT26.04.2016
Former [2016/36]AT23.12.2015
CZ23.12.2015
EE23.12.2015
ES23.12.2015
FI23.12.2015
IT23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
PL23.12.2015
RO23.12.2015
SE23.12.2015
SK23.12.2015
GR24.03.2016
Former [2016/35]CZ23.12.2015
ES23.12.2015
FI23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
SE23.12.2015
GR24.03.2016
Former [2016/34]CZ23.12.2015
FI23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
SE23.12.2015
GR24.03.2016
Former [2016/26]FI23.12.2015
LT23.12.2015
LV23.12.2015
NL23.12.2015
SE23.12.2015
GR24.03.2016
Former [2016/25]FI23.12.2015
LT23.12.2015
LV23.12.2015
SE23.12.2015
GR24.03.2016
Former [2016/24]FI23.12.2015
LT23.12.2015
SE23.12.2015
GR24.03.2016
Former [2016/20]LT23.12.2015
Cited inInternational search[DXY]WO2004056847  (GENMAB AS [DK], et al) [DX] 42-44,46,47,42-44,46,47,42-44,46,47 * page 20 * * page 65, paragraph 4 * * figures 13,14 * * claims 7,19-24,42-47 * * page 20 * * page 65, paragraph 4 * * figures 13,14 * * claims 7,19-24,42-47 * * page 20 * * page 65, paragraph 4 * * figures 13,14 * * claims 7,19-24,42-47 * [Y] 1-35,45,1-35,45,1-35,45;
 [DXY]WO2004058797  (MEDAREX INC [US], et al) [DX] 42-44,46,47,42-44,46,47,42-44,46,47 * page 45 * * example 2 * * claim 7 * * page 45 * * example 2 * * claim 7 * * page 45 * * example 2 * * claim 7 * [Y] 1-35,45,1-35,45,1-35,45;
 [X]  - SALCEDO ROSALBA ET AL, "Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 2002, (200208), vol. 8, no. 8, ISSN 1078-0432, pages 2655 - 2665, XP002451870 [X] 1-47,1-47,1-47 * the whole document * * the whole document * * the whole document *
    [ ] - GENESEQ, Derwent, (20040923), Database accession no. ADQ26403, URL: HTTP://WWW.EBI.AC.UK/CGI-BIN/EPO/EPOFETCH [ ] * column A * * column A * * column A *
    [ ] - GENESEQ, Derwent, (20041007), Database accession no. ADQ75769, URL: HTTP://WWW.EBI.AC.UK/CGI-BIN/EPO/EPOFETCH [ ] * column A * * column A * * column A *
    [ ] - GENESEQ, Derwent, (20041007), Database accession no. ADQ75777, URL: HTTP://WWW.EBI.AC.UK/CGI-BIN/EPO/EPOFETCH [ ] * column A * * column A * * column A *
 [A]  - PÉREZ-SOLER ROMÁN ET AL, "HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.", THE ONCOLOGIST MAY 2005, (200505), vol. 10, no. 5, ISSN 1083-7159, pages 345 - 356, XP002451871 [A] 1-47,1-47,1-47 * the whole document * * the whole document * * the whole document *

DOI:   http://dx.doi.org/10.1634/theoncologist.10-5-345
 [PX]  - HOCHSTER H S ET AL, "Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer", CANCER 15 AUG 2006 UNITED STATES, (20060717), vol. 107, no. 4, ISSN 0008-543X 1097-0142, pages 676 - 685, XP002451872 [PX] 1-47,1-47,1-47 * the whole document * * the whole document * * the whole document *
 [A]  - MASCIA F ET AL, "Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, (200307), vol. 163, no. 1, ISSN 0002-9440, pages 303 - 312, XP002410413 [A] 1-47,1-47,1-47 * the whole document * * the whole document * * the whole document *
 [A]  - KARASHIMA T ET AL, "INHIBITION OF ANGIOGENESIS BY THE ANTIEPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY IMCLONE C225 IN ANDROGEN-INDEPENDENT PROSTATE CANCER GROWING ORTHOTOPICALLY IN NUDE MICE", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (200205), vol. 8, no. 4, ISSN 1078-0432, pages 1253 - 1264, XP001149163 [A] 1-47,1-47,1-47 * the whole document * * the whole document * * the whole document *
 [A]  - BRUNS C J ET AL, "EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKADE WITH C225 PLUS GEMCITABINE RESULTS IN REGRESSION OF HUMAN PANCREATIC CARCINOMA GROWING ORTHOTOPICALLY IN NUDE MICE BY ANTIANGIOGENIC MECHANISMS", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (200005), vol. 6, ISSN 1078-0432, pages 1936 - 1948, XP002951102 [A] 1-47,1-47,1-47 * abstract * * abstract * * abstract *
 [A]  - ASAKUMA ET AL, "Modulation of Tumor Growth and Tumor Induced Angiogenesis After Epidermal Growth Factor Receptor Inhibition by ZD1839 in Renal Cell Carcinoma", JOURNAL OF UROLOGY, BALTIMORE, MD, US, (200402), vol. 171, no. 2, ISSN 0022-5347, pages 897 - 902, XP005532687 [A] 1-47,1-47,1-47 * abstract * * abstract * * abstract *

DOI:   http://dx.doi.org/10.1097/01.ju.0000095445.79222.ff
Examination   - Nannie Bangsgaard ET AL, "Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor", PLoS ONE, (20120625), vol. 7, no. 6, doi:10.1371/journal.pone.0039706, page e39706, XP055172165

DOI:   http://dx.doi.org/10.1371/journal.pone.0039706
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.